| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
71,730,000 |
| Market
Cap: |
393.80(M) |
| Last
Volume: |
668,077 |
Avg
Vol: |
963,466 |
| 52
Week Range: |
$4.4 - $8.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 621 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Orasure Technologies is engaged in two segments Diagnostics, and Molecular Solutions. Co.'s Diagnostics business primarily consists of the development, manufacture, marketing and sale of simple, easy to use diagnostic products and specimen collection devices using its proprietary technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Co.'s Molecular Solutions products primarily consist of collection kits and services used by clinical laboratories, direct-to-consumer laboratories, researchers, pharmaceutical companies, and animal health service and product providers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
100,000 |
170,200 |
| Total Buy Value |
$0 |
$0 |
$492,810 |
$781,522 |
| Total People Bought |
0 |
0 |
1 |
5 |
| Total Buy Transactions |
0 |
0 |
1 |
5 |
| Total Shares Sold |
0 |
24,129 |
25,887 |
25,887 |
| Total Sell Value |
$0 |
$194,219 |
$205,646 |
$205,646 |
| Total People Sold |
0 |
1 |
2 |
2 |
| Total Sell Transactions |
0 |
1 |
2 |
2 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Smith Brian |
EVP & BU Lead - Molecular |
• – – |
2018-02-15 |
4 |
S |
$17.95 |
$179,450 |
D/D |
(10,000) |
18,075 |
|
- |
|
| Smith Brian |
EVP & BU Lead - Molecular |
• – – |
2018-02-15 |
4 |
OE |
$5.96 |
$59,590 |
D/D |
10,000 |
28,075 |
|
- |
|
| Zezzo Ii Anthony |
EVP & BU Lead - Infectious |
• – – |
2018-02-03 |
4 |
D |
$21.00 |
$29,022 |
D/D |
(1,382) |
148,383 |
|
- |
|
| Jerrett Jack E |
SVP & General Counsel |
• – – |
2018-02-03 |
4 |
D |
$21.00 |
$38,619 |
D/D |
(1,839) |
50,268 |
|
- |
|
| Michels Douglas A |
President & CEO |
• • – |
2018-02-03 |
4 |
D |
$21.00 |
$183,456 |
D/D |
(8,736) |
716,939 |
|
- |
|
| Smith Brian |
EVP & BU Lead - Molecular |
• – – |
2018-02-03 |
4 |
D |
$21.00 |
$21,357 |
D/D |
(1,017) |
18,075 |
|
- |
|
| Kuna Mark L |
SVP & Controller |
• – – |
2018-02-03 |
4 |
D |
$21.00 |
$27,426 |
D/D |
(1,306) |
49,213 |
|
- |
|
| Spair Ronald H |
COO & CFO |
• • – |
2018-02-03 |
4 |
D |
$21.00 |
$4,788 |
I/I |
(228) |
166,402 |
|
- |
|
| Reed Michael |
SVP R&D and CSO |
• – – |
2018-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
3,593 |
31,921 |
|
- |
|
| Reed Michael |
SVP R&D and CSO |
• – – |
2018-02-01 |
4 |
D |
$21.65 |
$40,736 |
D/D |
(1,882) |
28,328 |
|
- |
|
| Zezzo Ii Anthony |
EVP & BU Lead - Infectious |
• – – |
2018-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,714 |
149,765 |
|
- |
|
| Zezzo Ii Anthony |
EVP & BU Lead - Infectious |
• – – |
2018-02-01 |
4 |
D |
$21.65 |
$115,996 |
D/D |
(5,359) |
140,051 |
|
- |
|
| Jerrett Jack E |
SVP & General Counsel |
• – – |
2018-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,755 |
52,107 |
|
- |
|
| Jerrett Jack E |
SVP & General Counsel |
• – – |
2018-02-01 |
4 |
D |
$21.65 |
$126,991 |
D/D |
(5,867) |
43,352 |
|
- |
|
| Michels Douglas A |
President & CEO |
• • – |
2018-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
36,615 |
725,675 |
|
- |
|
| Michels Douglas A |
President & CEO |
• • – |
2018-02-01 |
4 |
D |
$21.65 |
$605,735 |
D/D |
(27,985) |
689,060 |
|
- |
|
| Smith Brian |
EVP & BU Lead - Molecular |
• – – |
2018-02-01 |
4 |
D |
$21.65 |
$92,489 |
D/D |
(4,273) |
19,092 |
|
- |
|
| Kuna Mark L |
SVP & Controller |
• – – |
2018-02-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,864 |
50,519 |
|
- |
|
| Kuna Mark L |
SVP & Controller |
• – – |
2018-02-01 |
4 |
D |
$21.65 |
$104,675 |
D/D |
(4,836) |
43,655 |
|
- |
|
| Spair Ronald H |
COO & CFO |
• • – |
2018-02-01 |
4 |
A |
$0.00 |
$0 |
I/I |
18,371 |
166,630 |
|
- |
|
| Spair Ronald H |
COO & CFO |
• • – |
2018-02-01 |
4 |
D |
$21.65 |
$21,212 |
I/I |
(980) |
148,259 |
|
- |
|
| Spair Ronald H |
COO & CFO |
• • – |
2018-01-16 |
4 |
A |
$20.80 |
$17,139 |
D/D |
824 |
109,890 |
|
- |
|
| Spair Ronald H |
COO & CFO |
• • – |
2018-01-16 |
4 |
D |
$20.80 |
$17,139 |
I/I |
(824) |
149,239 |
|
- |
|
| Michels Douglas A |
President & CEO |
• • – |
2018-01-10 |
4 |
GD |
$19.39 |
$59,915 |
D/D |
3,090 |
717,045 |
|
- |
|
| Patrick Charles W |
Director |
– • – |
2017-11-21 |
4 |
D |
$15.25 |
$120,811 |
D/D |
(7,922) |
58,182 |
|
- |
|
823 Records found
|
|
Page 10 of 33 |
|
|
0.01 (0.18%) 
